奥拉西坦联合鼠神经生长因子治疗重型脑外伤的临床观察及其对血清神经元特异性烯醇化酶的影响

The Clinical Observation of Oxiracetam with Mouse Nerve Growth Factor in the Treatment of Severe Craniocerebral Injury and Its Effect on Serum Neuronal Specific Enolase

目的:探讨奥拉西坦注射液联合鼠神经生长因子治疗急性重型颅脑损伤的临床效果及其对血清神经元特异性烯醇化酶(neuron-specific enolase NSE)的影响。方法:选择福建中医院大学附属人民医院收治的60例重型颅脑损伤患者,对照组30例给予常规方法治疗14 d。治疗组在对照组常规方法治疗基础上加用奥拉西坦注射液和鼠神经生长因子治疗14 d。观察两组治疗前后格拉斯哥昏迷评分(GCS)、Glasgow(GOS)评分情况以及治疗过程中NSE的变化情况。结果:治疗组治疗第7、14天GCS评分、GOS评分良好率较对照组好,治疗第7天的NSE水平较低,差异有统计学意义(P<0.05)。结论:奥拉西坦注射液联合神经生长因子治疗重型急性颅脑损伤具有较好的临床效果,能够改善预后情况,降低NSE水平,具有一定的临床推广应用价值。

Objective：To investigate the clinical effect of Oxiracetam for injection combined with Mouse Nerve Growth Factor on acute severe craniocerebral injury and its effect on the serum neuron specific enolase（NSE）.Method：Sixty patients with severe craniocerebral injury in the Affiliated People＇s Hospital of Fujian University of Traditional Chinese Medicine were selected,and 30 patients in the control group were treated with normal treatment for 14 days.The treatment group based on conventional treatment were treated with the injection of Oxiracetam and Mouse Nerve Growth Factor for 14 days.The Glasgow Coma Scale（GCS）,Glasgow（GOS） score were observed before and after treatment and the change of NSE in the course of treatment was observed in the two groups.Result：The scores of GCS at the seventh and fourteenth day of the treatment and the good rate of GOS in the treatment group were better than the control group,the NSE level at the 7 th day of the treatment group was lower,the differences were statistically significant（P〈0.05）.Conclusion：Oxiracetam for injection combined with Mouse Nerve Growth Factor in the treatment of severe craniocerebral injury has better clinical efficacy,can improve the prognosis,reduce the level of NSE,which has certain clinical application value.